Document is current
Any future updates will be listed below
-
Authors
Nakatani, Shinya https://orcid.org/0000-0001-5302-3634
Morioka, Fumiyuki
Uedono, Hideki
Tsuda, Akihiro
Mori, Katsuhito
Emoto, Masanori
- License Information
-
More Information
Article History
Received: 4 June 2023
Accepted: 11 November 2023
First Online: 20 December 2023
Declarations
:
: None of the authors have conflicts of interests to declare in regard to dapagliflozin. Regarding SGLT2 inhibitors other than dapagliflozin, KM has received honorariums for lecturing from Mitsubishi Tanabe Pharma Corporation, AstraZeneca K.K., and Nippon Boehringer Ingelheim. KM and ME have received research funding from Tanabe Pharma Corporation.
: This article does not contain results of any studies with human participants or animals performed by any of the authors.
: Written informed consent was obtained from the patient for publication of her clinical data.
